PURE - PURE Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4000
0.0000 (0.00%)
At close: 3:03PM EDT
Stock chart is not supported by your current browser
Previous Close0.4000
Open0.4100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4000 - 0.4100
52 Week Range0.2900 - 0.8900
Volume3,725
Avg. Volume24,170
Market Cap29.645M
Beta (3Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PURE earnings conference call or presentation 6-Mar-19 9:30pm GMT

    Q2 2019 PURE Biosciences Inc Earnings Call

  • Business Wire2 months ago

    PURE Bioscience Reports Fiscal 2019 Second Quarter and Six-Month Financial Results

    Update on SDC-Based Antimicrobial Food Safety Solutions

  • Business Wire2 months ago

    PURE Bioscience and SmartWash Solutions Announce Partnership for New Combined PURE Control®/SmartWash™ Antimicrobial Treatment for Produce

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and SmartWash Solutions announced a partnership for a revolutionary antimicrobial pre-treatment on cut produce named SmartWash Boost™. SmartWash Boost, the new combined application of PURE Control with SmartWash, takes produce food safety to a revolutionary new level, 99.8% lethality.

  • Business Wire2 months ago

    PURE Bioscience Sets Fiscal 2019 Second Quarter and Six-Month Financial Results Call

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on March 6, 2019 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30pm PT (4:30pm ET) to review fiscal 2019 second quarter and six-month financial results. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PURE earnings conference call or presentation 25-Oct-18 8:30pm GMT

    Full Year 2018 PURE Biosciences Inc Earnings Call

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of PURE earnings conference call or presentation 13-Dec-18 9:30pm GMT

    Q1 2019 PURE Biosciences Inc Earnings Call

  • Business Wire4 months ago

    PURE Bioscience Reports Fiscal 2019 Q1 Financial Results

    Commercialization Updates on PURE Control® and PURE® Hard Surface Antimicrobial Food Safety Solutions

  • Business Wire5 months ago

    PURE Bioscience Sets Fiscal 2019 Q1 Financial Results Conference Call

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on December 13, 2018 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30 p.m. PT (4:30 p.m. ET) to review fiscal 2019 Q1 financial results. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds.

  • Business Wire5 months ago

    PURE Bioscience to Present at the 11th Annual LD Micro Conference

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that Hank R. Lambert, CEO, will present at the 11th Annual LD Micro Conference on Wednesday, December 5th at 11:00 am PT, at the Luxe Hotel Sunset Boulevard in Los Angeles. The presentation will be webcast live and slides may be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/.

  • Business Wire6 months ago

    PURE Bioscience Reports Fiscal 2018 Year-End Financial Results

    Update on PURE’s SDC-Based Antimicrobial Food Safety Solutions Outlook

  • Business Wire7 months ago

    PURE Bioscience Sets Conference Call to Report 2018 Fiscal Year-End Financial Results

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on October 25, 2018 the Company will file its Form 10-K shortly after the close of the market and will host an investor conference call that day at 1:30pm PT (4:30pm ET) to review fiscal 2018 YE financial results. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance.

  • Business Wire7 months ago

    PURE Bioscience Appoints Chief Operating Officer

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that Tom Myers has been promoted to Chief Operating Officer. Myers will be responsible for sales (including the Company’s direct sales force, consultants and growing distributor network), marketing, technical services, operations and engineering. Myers has been with PURE for seven years and for the past two years has served as PURE’s Executive Vice President, Technical Support Services.

  • Business Wire8 months ago

    PURE Bioscience Closes on $1.5 Million Financing and Provides Business Update

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that it has closed on an approximately $1.5 million private placement with existing shareholders. The $1.5 million the company raised includes cancelled indebtedness held by the Company’s director, Tom Y. Lee, of approximately $504,000. The shares were offered and sold pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

  • TheStreet.com9 months ago

    Small-Cap Cannabis Firms Raise Millions in Growth Cash

    Several micro-cap and private companies in Canada have raised millions this week to boost their cannabis businesses as the industry scales up. The transactions come as Canada prepares for the start in mid-October of legal adult use of recreational marijuana. Market participants told Real Money the flurry of deals fits Canada's tradition of financing emerging businesses through small-cap stock, reverse merger listings and private placements.

  • CNW Group9 months ago

    IIROC Trading Resumption - PURE

    IIROC Trading Resumption - PURE

  • Business Wire10 months ago

    PURE Bioscience Raises $500,000 in Unsecured Promissory Note - Appoints Ivan Chen to Board of Directors

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that it has raised $500,000 in the form of a promissory note from Tom Lee, a member of PURE’s Board of Directors and its largest shareholder. Hank R. Lambert, CEO of PURE said, “This non-dilutive interim financing supports our ongoing operations as we continue to expand use by existing customers and garner new users for our SDC-based food safety solutions. PURE also announced that it has named attorney and entrepreneur Ivan Chen to its Board of Directors, filling the vacancy left by the retirement of Director William Otis.

  • Thomson Reuters StreetEvents10 months ago

    Edited Transcript of PURE earnings conference call or presentation 13-Jun-18 8:30pm GMT

    Q3 2018 PURE Biosciences Inc Earnings Call

  • Business Wire10 months ago

    PURE Bioscience Reports Fiscal 2018 Third Quarter and Nine-Month Financial Results

    PURE Bioscience, Inc. , creator of the patented non-toxic silver dihydrogen citrate antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2018.

  • Business Wire11 months ago

    PURE Bioscience Sets Conference Call to Report 2018 Fiscal Third Quarter and Nine-Month Financial Results

    PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on June 13, 2018 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30pm PT (4:30pm ET) to review fiscal 2018 Q3 financial results. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance.

  • Business Wirelast year

    PURE Bioscience Responds to the Latest Foodborne Illness Outbreak Tied to Romaine Lettuce

    PURE Bioscience, Inc. , creator of the patented silver dihydrogen citrate antimicrobial, today responded to the current widespread foodborne illness outbreak associated with romaine lettuce.